Acrivon therapeutics to reveal the molecular mechanisms driving strong single-agent activity of acr-2316, its ap3-enabled clinical stage wee1/pkmyt1 inhibitor, at the aacr annual meeting 2025

Presentation to highlight how ap3 generative phosphoproteomic analyses uncover how acr-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically

ACRV Ratings Summary

ACRV Quant Ranking